Condition: Healthy
Interventions: Biological: Ad26.Mos4.HIV; Biological: Clade C and Mosaic gp140 HIV bivalent vaccine; Biological: Placebo
Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
June 1, 2019ClinicalTrials.govComments OffInfections and Infectious DiseasesAdenovirus | Adjuvanted | Among | and/or | Cisgender | Clade | gp140 | Heterologous | HIV1 | Human | Immunodeficiency | Individuals | Infection | Mosaic | Mosaic4 | Prevent | Regimen | Serotype | Study | Transgender | Vaccine | VirusAd26.Mos4.HIV
Comments
